Zacks: Analysts Expect Cocrystal Pharma, Inc. (NASDAQ:COCP) Will Post Quarterly Sales of $380,000.00

Wall Street analysts predict that Cocrystal Pharma, Inc. (NASDAQ:COCPGet Rating) will announce sales of $380,000.00 for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Cocrystal Pharma’s earnings. The lowest sales estimate is $250,000.00 and the highest is $500,000.00. The business is expected to announce its next earnings results on Monday, January 1st.

On average, analysts expect that Cocrystal Pharma will report full-year sales of $1.38 million for the current fiscal year, with estimates ranging from $750,000.00 to $2.00 million. For the next fiscal year, analysts forecast that the company will post sales of $9.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that cover Cocrystal Pharma.

Cocrystal Pharma (NASDAQ:COCPGet Rating) last issued its quarterly earnings data on Wednesday, May 11th. The company reported ($0.04) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.04).

COCP has been the topic of several analyst reports. Noble Financial reaffirmed a “buy” rating and issued a $5.00 price target on shares of Cocrystal Pharma in a report on Thursday, May 12th. HC Wainwright reaffirmed a “buy” rating and issued a $4.00 price target on shares of Cocrystal Pharma in a report on Monday, March 14th.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in COCP. Raymond James Financial Services Advisors Inc. lifted its stake in shares of Cocrystal Pharma by 108.7% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 24,243 shares of the company’s stock worth $25,000 after buying an additional 12,625 shares during the period. Barclays PLC lifted its stake in shares of Cocrystal Pharma by 248.5% during the third quarter. Barclays PLC now owns 26,665 shares of the company’s stock worth $28,000 after buying an additional 19,014 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of Cocrystal Pharma by 14.3% during the third quarter. Goldman Sachs Group Inc. now owns 157,952 shares of the company’s stock worth $166,000 after buying an additional 19,784 shares during the period. LPL Financial LLC lifted its stake in shares of Cocrystal Pharma by 12.2% during the fourth quarter. LPL Financial LLC now owns 200,250 shares of the company’s stock worth $130,000 after buying an additional 21,750 shares during the period. Finally, Two Sigma Advisers LP acquired a new stake in shares of Cocrystal Pharma during the third quarter worth $60,000. 15.43% of the stock is currently owned by institutional investors and hedge funds.

COCP stock traded down $0.01 during trading on Friday, hitting $0.38. 167,690 shares of the company’s stock traded hands, compared to its average volume of 277,826. The firm has a market capitalization of $37.04 million, a P/E ratio of -2.38 and a beta of 1.13. The business has a fifty day simple moving average of $0.50 and a two-hundred day simple moving average of $0.61. Cocrystal Pharma has a 1 year low of $0.37 and a 1 year high of $1.49.

Cocrystal Pharma Company Profile (Get Rating)

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections.

Featured Articles

Get a free copy of the Zacks research report on Cocrystal Pharma (COCP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.